23andMe (NASDAQ:ME) Earns Sell (E+) Rating from Weiss Ratings

23andMe (NASDAQ:ME)‘s stock had its “sell (e+)” rating reissued by equities researchers at Weiss Ratings in a report released on Saturday,Weiss Ratings reports.

23andMe Stock Performance

Shares of NASDAQ ME opened at $1.79 on Friday. The stock has a market cap of $48.02 million, a price-to-earnings ratio of -0.12 and a beta of 1.19. The business has a 50 day simple moving average of $2.55 and a 200 day simple moving average of $3.93. 23andMe has a 52 week low of $1.34 and a 52 week high of $12.76.

23andMe (NASDAQ:ME) last announced its quarterly earnings results on Tuesday, January 28th. The company reported ($1.02) EPS for the quarter. 23andMe had a negative net margin of 183.39% and a negative return on equity of 170.07%.

Institutional Investors Weigh In On 23andMe

A number of large investors have recently added to or reduced their stakes in the stock. Shay Capital LLC boosted its position in 23andMe by 71.7% during the fourth quarter. Shay Capital LLC now owns 702,530 shares of the company’s stock worth $2,283,000 after purchasing an additional 293,358 shares during the period. Virtu Financial LLC bought a new stake in 23andMe during the fourth quarter worth approximately $49,000. Leavell Investment Management Inc. bought a new stake in 23andMe during the fourth quarter worth approximately $32,000. MassMutual Private Wealth & Trust FSB bought a new stake in 23andMe during the fourth quarter worth approximately $40,000. Finally, FNY Investment Advisers LLC bought a new stake in 23andMe during the fourth quarter worth approximately $26,000. Institutional investors own 36.10% of the company’s stock.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.